Short-interval follow-up MRI is an effective tool for identifying early-stage breast cancer, according to findings to be presented at the American Roentgen Ray Society (ARRS) 2019 Annual Meeting in Honolulu.

Providers should turn to ultrasound first, not mammography, when imaging palpable lumps after a mastectomy, according to new findings published in the American Journal of Roentgenology.

Peptide radionuclide therapy (PRRT) demonstrated long-term effectiveness in patients with malignant neuroendocrine tumors, reported authors of a study published in the Journal of Nuclear Medicine.

The joint statement—published in Thyroid—was put out by American Thyroid Association, the European Association of Nuclear Medicine, the Society of Nuclear Medicine and Molecular Imaging and the European Thyroid Association.

Mayfair Diagnostics (Calgary, Canada) has purchased 10 Carestream imaging systems including three CARESTREAM DRX-Evolution/DRX-Evolution Plus digital radiography systems (see video link), two CARESTREAM DRX-Ascend Systems and five CARESTREAM DRX-1 Systems to upgrade their existing medical imaging systems. These imaging systems are located throughout Mayfair’s network of 14 clinics.

Omron Healthcare launched its latest innovation, Complete, May 1, marking the first time a blood pressure (BP) monitor with electrocardiogram (ECG) capabilities has hit the commercial market.

Targeted breast ultrasound should be the first-line imaging test in patients with palpable lumps after mastectomy. Mammography can help confirm suspected cases, but did not find any additional cancers.

Johns Hopkin’s researchers have created a PET-based approach that can direct cancer drugs to precise points in the brains of mice, according to a study published in the May 1 edition of the Journal of Nuclear Medicine. If proven effective in humans, the researchers believe their technique could help patients with difficult brain tumors, such as glioblastomas.